Zilico Ltd announce charity partnership with Jo’s Cervical Cancer Trust

Tuesday 18th June 2019

Zilico Ltd, the company behind ZedScan™, a diagnostic device proven to improve the detection of cervical abnormalities which can develop into cervical cancer, are proud to announce their corporate partnership with Jo’s Cervical Cancer Trust.

The company will make a 50p donation to Jo’s for every ZedScan single-use EIS sensor sold, with a minimum contribution of £5000 during the partnership. These donations will help fund the charity’s activities supporting those affected by cervical cancer, promoting awareness of cervical cancer and the importance of cervical screening and HPV vaccination.

Zilico CEO, Sameer Kothari, is delighted that the uptake of ZedScan devices by colposcopy clinics across the UK has allowed the company to further support the charity, “At Zilico, we share Jo’s vision that cervical cancer can one day become a disease of the past, and we are dedicated to being part of that legacy. As a corporate partner, we are proud to be making a difference to the lives of people affected by cervical cancer. The fundraising through our sensor sales supports the fantastic work that Jo’s does every day and enables them to reach more people affected by this disease”.

Jo’s Cervical Cancer Trust, a UK charity dedicated to people affected by cervical cancer and cervical abnormalities, share the same vision: to eradicate cervical cancer and make it a disease of the past. Two women die every day in the UK from cervical cancer, but the disease itself can be prevented if cervical abnormalities are detected early. Regular cervical screening and the use of ZedScan as an adjunct to colposcopy can help healthcare professionals detect and treat cell changes (abnormalities) before cancer develops and also give patients reassurance when the absence of disease is confirmed.

Rob Music, Chief Executive for Jo’s says of the partnership, “Cervical cancer is a devastating disease and we want to be there for everyone affected, the funds raised by Zilico will help us be there for even more people at the time when they need us the most. We are truly grateful to have their support and look forward to working with them over the coming years.” 

ENDS

For media enquiries please contact:

Ryan Gibson

rgibson@onyxhealth.com

0191 640 3638

For corporate/product enquiries please contact:

Zilico Limited

info@zilico.co.uk

+44 (0)161 826 7840

Notes for editors

Colposcopy: where women are referred if abnormalities or recurring HPV are detected at screening

About Zilico Limited (Manufacturers of ZedScan™)

Zilico was founded in 2006 following a successful collaboration between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, UK, to develop a more accurate means of diagnosis for cervical intraepithelial neoplasia (CIN). Zilico's head office is located in Manchester, UK. Manufacturing and R&D functions are also carried out in the UK.

Many diseases still rely on visual diagnosis by a clinician. Zilico has developed a technology which recognises the changes in tissue structure using the electrical properties of cells. This non-visual technique allows for earlier detection and therefore allowing for appropriate intervention which can prevent the disease from further progression.

ZedScan, Zilico’s flagship product, a diagnostic in the cervical cancer pathway is now in routine use across several NHS hospitals. The ability to identify correctly those women who have and those who do not have disease is pivotal to the success of any screening programme and when used, ZedScan has demonstrated greater accuracy in detecting cervical disease and hence helping better management of patients.

Cervical cancer is the 4th most common cancer in women globally and the 14th most common cancer in the UK with 3,200 new cases diagnosed each year and is responsible for 270,000 deaths annually worldwide. The disease can be treated if diagnosed early, particularly at the pre-cancerous or cervical intra-epithelial neoplasia (CIN) stage.

The company has developed its patented Electrical Impedance Spectroscopy (EIS) into a platform technology for cancer diagnosis and is expanding its product development into other clinical areas

About Jo’s Cervical Cancer Trust

Jo’s Cervical Cancer Trust is a UK charity dedicated to women, their families and friends affected by cervical cancer and cervical abnormalities. Their mission is to see cervical cancer prevented and reduce the impact for everyone affected by cervical abnormalities and cervical cancer through providing the highest quality information and support, and campaigning for excellence in cervical cancer treatment and prevention.

The trust was established in 1999 by James Maxwell, after his wife, Jo, passed away from cervical cancer. It was Jo's wish that every woman affected by cervical cancer gets the support and information they need.

Charity number: 1133542/SC041236

News